Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol 2014; 20(36): 13159-13166 [PMID: 25278711 DOI: 10.3748/wjg.v20.i36.13159]
Corresponding Author of This Article
Zhong-Yang Shen, MD, PhD, Department of Organ Transplantation, Tianjin Key Laboratory of Organ Transplantation, Tianjin First Central Hospital, Fukang Road 24, Tianjin 300192, China. shenzhongyangmd@126.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2014; 20(36): 13159-13166 Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.13159
Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation
Wei Rao, Man Xie, Tao Yang, Jian-Jun Zhang, Wei Gao, Yong-Lin Deng, Hong Zheng, Cheng Pan, Yi-He Liu, Zhong-Yang Shen
Wei Rao, Tao Yang, Wei Gao, Yong-Lin Deng, Hong Zheng, Cheng Pan, Yi-He Liu, Zhong-Yang Shen, Jian-jun Zhang, Department of Organ Transplantation, Tianjin Key Laboratory of Organ Transplantation, Tianjin First Central Hospital, Tianjin 300192, China
Man Xie, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Author contributions: Rao W and Xie M contributed equally to this work; Rao W and Xie M performed the majority of experiments; Yang T, Gao W and Zhang JJ provided vital reagents and were also involved in editing the manuscript; Deng YL, Zheng H, Pan C and Liu YH co-ordinated and provided the collection of all the human material; Shen ZY contributed to the design and interpretation of the study.
Supported by National High Technology Research and Development Program (863 Program) of China, No. 2012AA021001
Correspondence to: Zhong-Yang Shen, MD, PhD, Department of Organ Transplantation, Tianjin Key Laboratory of Organ Transplantation, Tianjin First Central Hospital, Fukang Road 24, Tianjin 300192, China. shenzhongyangmd@126.com
Telephone: +86-22-23626612 Fax: +86-22-23626612
Received: January 23, 2014 Revised: May 12, 2014 Accepted: June 26, 2014 Published online: September 28, 2014 Processing time: 251 Days and 5.5 Hours
Core Tip
Core tip: We reported our experience of de novo hepatitis B virus (HBV) infection after pediatric living donor liver transplantation (LDLT), which showed that the incidence of de novo HBV infection in pediatric LDLT was 16.7% in our center. Among hepatitis B core antibody (HBcAb)-positive allografts, 43.7% were intrahepatic HBV DNA positive. Positive intrahepatic HBV DNA in allografts was predictive of de novo HBV infection after LDLT in children who were given HBcAb-positive allografts. Hepatitis B surface antibody/HBcAb positivity exhibited weak effectiveness in preventing children receiving HBcAb-positive allografts from de novo HBV infection. Lamivudine prophylaxis therapy is essential to prevent de novo HBV infection in pediatric patients from HBcAb-positive allografts with positive intrahepatic HBV DNA.
